Trade Sio Gene Therapies Inc. - SIOX CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Sio Gene Therapies Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.26-0.47 |
| Average Volume (10 days) | 43.08K |
| Average Volume (3 months) | 833.87K |
| Market Cap | 28.11M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 73.98M |
| Revenue | N/A |
| EPS | -0.39 |
| Dividend (Yield %) | N/A |
| Beta | 1.40 |
| Next Earnings Date | Sep 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Sio Gene Therapies Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, September 25, 2023 | ||
| Time (UTC) 11:00 | Country US
| Event Q1 2024 Sio Gene Therapies Inc Earnings Release Q1 2024 Sio Gene Therapies Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q2 2024 Sio Gene Therapies Inc Earnings Release Q2 2024 Sio Gene Therapies Inc Earnings ReleaseForecast -Previous - |
| Monday, February 12, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2024 Sio Gene Therapies Inc Earnings Release Q3 2024 Sio Gene Therapies Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 71.562 | 42.197 | 69.171 | 127.018 | 213.318 |
| Selling/General/Admin. Expenses, Total | 18.163 | 17.294 | 22.061 | 39.466 | 71.906 |
| Research & Development | 53.399 | 24.903 | 47.11 | 87.552 | 141.412 |
| Operating Income | -71.562 | -42.197 | -69.171 | -127.018 | -213.318 |
| Interest Income (Expense), Net Non-Operating | -0.027 | -0.799 | -4.377 | -7.53 | -7.545 |
| Other, Net | -0.039 | 10.359 | 1.358 | 5.616 | 0.211 |
| Net Income Before Taxes | -71.628 | -32.637 | -72.19 | -128.932 | -220.652 |
| Net Income After Taxes | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Net Income Before Extra. Items | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Net Income | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Income Available to Common Excl. Extra. Items | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Income Available to Common Incl. Extra. Items | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Diluted Net Income | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Diluted Weighted Average Shares | 73.2116 | 52.1814 | 24.8125 | 16.1007 | 13.422 |
| Diluted EPS Excluding Extraordinary Items | -0.98191 | -0.62139 | -2.92707 | -8.01612 | -16.5082 |
| Diluted Normalized EPS | -0.98191 | -0.62139 | -2.92707 | -8.01612 | -16.5082 |
| Total Extraordinary Items | 0 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 4.483 | 3.277 | 8.534 | 13.076 | 25.373 |
| Selling/General/Admin. Expenses, Total | 2.6 | 2.941 | 2.992 | 0.47 | 4.086 |
| Research & Development | 1.883 | 0.336 | 5.542 | 12.606 | 21.287 |
| Operating Income | -4.483 | -3.277 | -8.534 | -13.076 | -25.373 |
| Interest Income (Expense), Net Non-Operating | -0.008 | -0.007 | |||
| Other, Net | 0.464 | 0.197 | 0.124 | 0.047 | -0.076 |
| Net Income Before Taxes | -4.019 | -3.08 | -8.41 | -13.037 | -25.456 |
| Net Income After Taxes | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Net Income Before Extra. Items | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Net Income | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Income Available to Common Excl. Extra. Items | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Income Available to Common Incl. Extra. Items | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Diluted Net Income | -4.019 | -3.08 | -8.406 | -13.324 | -25.456 |
| Diluted Weighted Average Shares | 73.9752 | 73.9752 | 73.7653 | 73.7056 | 73.3353 |
| Diluted EPS Excluding Extraordinary Items | -0.05433 | -0.04164 | -0.11396 | -0.18077 | -0.34712 |
| Diluted Normalized EPS | -0.05433 | -0.04164 | -0.11396 | -0.18077 | -0.34712 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 71.736 | 132.333 | 85.43 | 114.584 | 158.262 |
| Cash and Short Term Investments | 63.729 | 118.986 | 80.752 | 106.999 | 154.337 |
| Cash & Equivalents | 63.729 | 118.986 | 80.752 | 106.999 | 154.337 |
| Total Receivables, Net | 1.609 | 5.999 | 1.707 | 1.726 | 1.751 |
| Prepaid Expenses | 5.214 | 7.348 | 2.971 | 5.859 | 2.174 |
| Total Assets | 75.08 | 135.147 | 93.68 | 122.706 | 160.786 |
| Property/Plant/Equipment, Total - Net | 3.344 | 1.63 | 2.333 | 1.278 | 2.524 |
| Other Long Term Assets, Total | 0 | 1.184 | 0.046 | 0.973 | 0 |
| Total Current Liabilities | 13.002 | 10.848 | 32.043 | 43.499 | 46.575 |
| Accounts Payable | 3.984 | 1.341 | 4.412 | 1.698 | 3.949 |
| Accrued Expenses | 7.291 | 8.733 | 10.361 | 17.315 | 29.573 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.727 | 0.774 | 1.847 | 3.304 | 3.3 |
| Total Liabilities | 14.732 | 11.78 | 32.122 | 66.493 | 89.5 |
| Total Long Term Debt | 0 | 0 | 0 | 22.994 | 42.925 |
| Long Term Debt | 0 | 22.994 | 42.925 | ||
| Total Equity | 60.348 | 123.367 | 61.558 | 56.213 | 71.286 |
| Common Stock | 0.001 | 0.001 | 0.0004 | 0.00023 | 0.001 |
| Additional Paid-In Capital | 922.966 | 914.1 | 820.257 | 741.318 | 628.11 |
| Retained Earnings (Accumulated Deficit) | -862.956 | -791.069 | -758.644 | -686.016 | -556.951 |
| Other Equity, Total | 0.337 | 0.335 | -0.0554 | 0.91077 | 0.126 |
| Total Liabilities & Shareholders’ Equity | 75.08 | 135.147 | 93.68 | 122.706 | 160.786 |
| Total Common Shares Outstanding | 73.7394 | 69.3776 | 39.5263 | 22.7799 | 13.4735 |
| Current Port. of LT Debt/Capital Leases | 0 | 15.423 | 21.182 | 9.753 | |
| Long Term Investments | 5.871 | 5.871 | |||
| Other Liabilities, Total | 1.73 | 0.932 | 0.079 | ||
| Other Current Assets, Total | 1.184 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 47.272 | 53.739 | 59.131 | 71.736 | 90.07 |
| Cash and Short Term Investments | 46.127 | 49.865 | 54.771 | 63.729 | 81.91 |
| Cash & Equivalents | 46.127 | 49.865 | 54.771 | 63.729 | 81.91 |
| Total Receivables, Net | 0.356 | 0.355 | 0.355 | 1.609 | 1.732 |
| Prepaid Expenses | 0.789 | 2.335 | 2.821 | 5.214 | 5.244 |
| Total Assets | 47.272 | 53.746 | 62.482 | 75.08 | 93.306 |
| Property/Plant/Equipment, Total - Net | 0 | 0.007 | 3.351 | 3.344 | 3.236 |
| Other Long Term Assets, Total | 0 | 0 | |||
| Total Current Liabilities | 2.152 | 4.834 | 9.149 | 13.002 | 15.138 |
| Accounts Payable | 0.201 | 1.963 | 2.24 | 3.984 | 6.611 |
| Accrued Expenses | 1.452 | 2.372 | 6.909 | 7.291 | 7.827 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 0.499 | 0.499 | 1.727 | 0.7 | |
| Total Liabilities | 2.152 | 4.834 | 10.703 | 14.732 | 17.041 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 0 | 1.554 | 1.73 | 1.903 |
| Total Equity | 45.12 | 48.912 | 51.779 | 60.348 | 76.265 |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 923.249 | 923.022 | 922.807 | 922.966 | 925.558 |
| Retained Earnings (Accumulated Deficit) | -878.461 | -874.442 | -871.362 | -862.956 | -849.632 |
| Other Equity, Total | 0.331 | 0.331 | 0.333 | 0.337 | 0.338 |
| Total Liabilities & Shareholders’ Equity | 47.272 | 53.746 | 62.482 | 75.08 | 93.306 |
| Total Common Shares Outstanding | 73.9752 | 73.9752 | 73.9752 | 73.7394 | 73.6971 |
| Other Current Assets, Total | 0 | 1.184 | 1.184 | 1.184 | 1.184 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -71.887 | -32.425 | -72.628 | -129.065 | -221.573 |
| Cash From Operating Activities | -60.346 | -46.589 | -67.473 | -134.207 | -190.348 |
| Cash From Operating Activities | 0.268 | 0.945 | 1.477 | 2.45 | 3.083 |
| Deferred Taxes | 0 | 2.709 | |||
| Non-Cash Items | 7.83 | -4.769 | 8.565 | 11.491 | 31.65 |
| Cash Taxes Paid | 0.005 | 0.04 | 0.562 | 0.071 | 0.377 |
| Cash Interest Paid | 0.027 | 0.465 | 4.012 | 6.376 | 6.365 |
| Changes in Working Capital | 3.443 | -10.34 | -4.887 | -19.083 | -6.217 |
| Cash From Investing Activities | 3.648 | 12.386 | -0.255 | -0.202 | -4.284 |
| Capital Expenditures | -0.695 | -0.398 | -0.255 | -0.202 | -4.284 |
| Other Investing Cash Flow Items, Total | 4.343 | 12.784 | 0 | ||
| Cash From Financing Activities | 1.441 | 73.621 | 41.481 | 87.071 | 136.396 |
| Financing Cash Flow Items | 0 | 0.121 | 0.148 | 1.894 | 0.324 |
| Issuance (Retirement) of Stock, Net | 1.441 | 89.231 | 70.896 | 94.884 | 136.072 |
| Net Change in Cash | -55.257 | 39.418 | -26.247 | -47.338 | -58.236 |
| Issuance (Retirement) of Debt, Net | 0 | -15.731 | -29.563 | -9.707 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -15.505 | -11.486 | -8.406 | -71.887 | -58.563 |
| Cash From Operating Activities | -18.686 | -13.764 | -8.681 | -60.346 | -42.524 |
| Cash From Operating Activities | 0.137 | 0.137 | 0.094 | 0.268 | 0.187 |
| Non-Cash Items | 3.584 | 3.35 | 0.013 | 7.83 | 10.253 |
| Changes in Working Capital | -6.902 | -5.765 | -0.382 | 3.443 | 5.599 |
| Cash From Investing Activities | -0.1 | -0.1 | -0.277 | 3.648 | 4.007 |
| Capital Expenditures | -0.29 | -0.29 | -0.277 | -0.695 | -0.336 |
| Other Investing Cash Flow Items, Total | 0.19 | 0.19 | 0 | 4.343 | 4.343 |
| Cash From Financing Activities | 0 | 0 | 0 | 1.441 | 1.441 |
| Financing Cash Flow Items | 0 | 0 | |||
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 1.441 | 1.441 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | |||
| Net Change in Cash | -18.786 | -13.864 | -8.958 | -55.257 | -37.076 |
Sio Gene Therapies Inc. Company profile
About Sio Gene Therapies Inc
Sio Gene Therapies Inc. is a clinical-stage company. The Company is focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The Company is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.
Financial summary
BRIEF: For the nine months ended 31 December 2021, Sio Gene Therapies Inc revenues was not reported. Net loss increased from $29.1M to $58.6M. Higher net loss reflects Research and development (includes $8,02 increase from $15.4M to $32.1M (expense), Stock-based Compensation in SGA increase from $2.3M to $8.1M (expense), Other expense (income) decrease from $1.4M (income) to $86K (expense).
| Industry: | Pharmaceuticals (NEC) |
1501 Broadway
12th FLOOR
NEW YORK
NEW YORK 10036
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com